Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs International Flavors & Fragrances Inc. Common Stock (IFF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs International Flavors & Fragrances Inc. Common Stock — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.03 (market cap $3.94B), while International Flavors & Fragrances Inc. Common Stock trades at $89.51 (market cap $22.50B). The key difference: International Flavors & Fragrances Inc. Common Stock is far larger — about 5.7× Edgewise Therapeutics Inc. Common Stock's market cap, and International Flavors & Fragrances Inc. Common Stock pays a 1.81% dividend while Edgewise Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and International Flavors & Fragrances Inc. Common Stock for 6 Days on average.
| EWTX | IFF | |
|---|---|---|
Market Cap | $3.94B | $22.50B |
Volume | 810,104 | 3,000,517 |
Sector | Health | Basic Materials |
52-Week High | $48.35 | $89.60 |
52-Week Low | $14.89 | $61.49 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $3.48B | $28.18B |
Dividend Yield | — | 1.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IFF trades at $88.2, up 3.81% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $361 million in 2025 but returned to profitability in 2026 with $277 million net income. Recent news highlights product innovations like AQUASCENT™ and life-stage dairy insights. Analyst consensus is strongly bullish with a $95 price target, though valuation ratios like P/E of 80.92 appear elevated relative to earnings.
The outlook for IFF hinges on sustaining its 2026 profitability turnaround and executing growth initiatives. Investment opportunities include market leadership in flavors and fragrances and new technology launches. Key risks are high debt levels, competitive pressures, and sensitivity to consumer spending trends. The stock's upside is supported by analyst optimism but requires careful monitoring of earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About International Flavors & Fragrances Inc. Common Stock
International Flavors & Fragrances develops ingredients and solutions used in food, beverages, personal care, home care, health, and biosciences applications. Its portfolio includes flavors, fragrances, cultures, enzymes, and nutrition ingredients.
Read more on IFF →
